Provided by Tiger Trade Technology Pte. Ltd.

ProMIS Neurosciences Inc

9.61
+0.46005.03%
Post-market: 9.610.00000.00%19:30 EDT
Volume:18.85K
Turnover:183.53K
Market Cap:86.18M
PE:-0.76
High:10.15
Open:9.06
Low:9.06
Close:9.15
52wk High:27.40
52wk Low:6.27
Shares:8.97M
Float Shares:4.39M
Volume Ratio:0.62
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.6200
EPS(LYR):-22.6100
ROE:-172.30%
ROA:-81.06%
PB:1.74
PE(LYR):-0.43

Loading ...

ProMIS Neurosciences is Maintained at Buy by Chardan Capital

Dow Jones
·
Jul 28

Chardan Adjusts Price Target on ProMIS Neurosciences to $33 From $20, Maintains Buy Rating

MT Newswires Live
·
Jul 28

ProMIS Neurosciences Inc : Chardan Capital Markets Raises Target Price to $33 from $20

THOMSON REUTERS
·
Jul 28

Analysts Offer Insights on Healthcare Companies: Opko Health (OPK), ProMIS Neurosciences (PMN) and The Ensign Group (ENSG)

TIPRANKS
·
Jul 28

ProMIS Reports Positive Six-month Interim Safety, Biomarker Data for Pmn310 in Phase 1b Alzheimer’s Trial

Reuters
·
Jul 28

ProMIS Neurosciences - no Aria-E Observed Across All Genotypes Including Apoe4 Homozygotes in Interim Analysis

THOMSON REUTERS
·
Jul 28

ProMIS Neurosciences - Early Biomarker Movement Consistent with Target Engagement Observed

THOMSON REUTERS
·
Jul 28

ProMIS Neurosciences - 12-Month Topline Results Expected in Q1 2027

THOMSON REUTERS
·
Jul 28

ProMIS Neurosciences Shares Rise on Upcoming Alzheimer's Trial Update

Dow Jones
·
Jul 28

ProMIS Neurosciences Initiated at Buy by Chardan Capital

Dow Jones
·
Jul 27

ProMIS Neurosciences initiated with a Buy at Chardan

TIPRANKS
·
Jul 27

Analysts Offer Insights on Healthcare Companies: Raffles Medical Group (OtherRAFLF), ProMIS Neurosciences (PMN) and Chugai Pharmaceutical Co (OtherCHGCF)

TIPRANKS
·
Jul 27

Promis Neurosciences Inc : Chardan Capital Markets Initiates Coverage with Buy Rating; Price Target $20

THOMSON REUTERS
·
Jul 27

Guggenheim Sticks to Their Buy Rating for ProMIS Neurosciences (PMN)

TIPRANKS
·
Jul 14

ProMIS Neurosciences reports amyloid-beta oligomer reduction by PMN310

TIPRANKS
·
Jul 14

Promis Neurosciences Says Pmn310 Cuts Amyloid-beta Oligomers in Human CSF in Phase 1a Data

Reuters
·
Jul 14

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

GlobeNewswire
·
Jul 14

Promis Neurosciences Initiated at Buy by Roth Capital

Dow Jones
·
Jul 08

ProMIS Neurosciences initiated with a Buy at Roth Capital

TIPRANKS
·
Jul 08

Promis Neurosciences Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Jun 30